Fig. 4

PLA2G16 is a target of lncROPM and associates with breast cancer development and chemo-resistance. A, B qRT-PCR analysis of PLA2G16 expression in BCSCs transfected with shCtrl or shROPM (A), or in non-BCSCs transfected with LEV and LV-ROPM lentivirus (B). C, D Western blotting analysis of PLA2G16 expression in BCSCs or non-BCSC as described in A and B. E Pearson correlation analysis of lncROPM and PLA2G16 expression in 130 breast cancer samples from our data. F Representative IHC images of PLA2G16 in breast cancer tissues. Original magnification, × 200. Scale bars, 100 µm. G qRT-PCR analysis of PLA2G16 expression in breast cancer chemosensitive tissues (n = 30) and chemoresistant tissues (n = 30) (left panel). Representative IHC images of PLA2G16 in tissues were shown in the right panel. Original magnification, × 200. Scale bars, 100 µm. H PLA2G16 expression in breast tumor samples from patients with pathologic complete response (pCR) and a partial response (pPR) to neoadjuvant paclitaxel/radiation treatment in GEO database (GSE22513). Data were presented as the mean ± SD, *p < 0.05, **p < 0.01